NeuraSignal noted that RapidPulse, Inc. raised a $48 million Series B funding round for their suction-based technology.

NeuraSignal is transforming stroke care with real-time access to cerebral blood flow, empowering clinicians to detect and prevent strokes with speed, accuracy, and automation. At the core of our mission is a bold belief: Eliminating stroke begins with real-time brain data, accessible to any provider, anywhere. Powered by AI and robotics, our flagship platform, NG2 Intelligent Ultrasound, delivers hands-free, autonomous transcranial Doppler (TCD) exams for the detection of right-to-left shunts (RLS), emboli, and cerebral vasospasm. Why it matters: up to 30% of strokes are cryptogenic, and traditional tools like TTE miss most PFOs. NG2 Intelligent Ultrasound detects 3x more PFOs than standard echo and identifies 2.7x more treatable shunts, giving clinicians the clarity to act, and patients the chance to prevent a second stroke. Fully reimbursable under existing CPT codes (93886, 93892, 93893), NG2 Intelligent Ultrasound brings diagnostic-grade neurovascular imaging to hospitals, ASCs, stroke centers, and rural clinics without relying on specialized techs. For clinicians seeking traditional, hands-on control, we also offer a manual version, the NG2 Classic Ultrasound. Beyond stroke care, our technology is proving vital across the full spectrum of traumatic brain injury (TBI). Because blood flow is fundamentally disrupted by both stroke and TBI, our systems are regularly utilized by neurocritical care teams to assess conditions ranging from mild concussions to severe, life-threatening brain injuries. Follow the NeuraSignal page and CEO Robert Hamilton for the latest updates on unlocking the power of blood flow data for stroke and TBI care.

Founded 2023